Bi-layer Tablet Segmentation for Rosuvastatin and Ezetimibe Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating a solid dosage form of rosuvastatin and ezetimibe that is bioequivalent to individual consumption is challenging due to rosuvastatin's oxidative and moisture-mediated degradation, ezetimibe's insolubility, and incompatibility with microcrystalline cellulose, which affects drug release and stability.
Innovation Solution
A bi-layer tablet formulation is developed, where rosuvastatin and ezetimibe are separated into distinct layers, using microcrystalline cellulose for rosuvastatin and lactose or mannitol for ezetimibe to enhance solubility, with specific excipients and processing steps to ensure stability and bioequivalence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If rosuvastatin and ezetimibe are combined in a single solid dosage form, then patient compliance and ease of administration are improved, but formulation stability and bioequivalence are compromised due to oxidative degradation, moisture sensitivity, and incompatibility with microcrystalline cellulose
Solution Approach 1:
The tablet is divided into two distinct layers: a first layer containing rosuvastatin with compatible excipients (lactose, mannitol, pregelatinized starch) and a second layer containing ezetimibe with compatible excipients (microcrystalline cellulose, croscarmellose sodium). This segmentation prevents direct interaction between the incompatible drugs while maintaining them in a single dosage form, thus improving compliance without compromising stability.
Solution Approach 2:
Each layer is formulated with locally optimized excipient combinations tailored to the specific stability and dissolution requirements of each drug. The rosuvastatin layer uses antioxidants and moisture barriers, while the ezetimibe layer uses excipients that enhance its solubility and release profile. This local optimization ensures both drugs maintain their individual properties within the combined formulation.
2Ease of manufacture
If microcrystalline cellulose is used as an excipient for rosuvastatin, then tablet compression and disintegration are improved, but ezetimibe solubility and drug release are retarded due to binding interactions
Solution Approach 1:
The formulation separates ezetimibe into a distinct second layer where microcrystalline cellulose is used exclusively for that drug. This eliminates the harmful binding interaction between microcrystalline cellulose and ezetimibe while still allowing microcrystalline cellulose to provide its compression and disintegration benefits in the ezetimibe layer.
Solution Approach 2:
The bi-layer structure acts as a physical intermediary that prevents direct contact between ezetimibe and incompatible excipients like microcrystalline cellulose when they would otherwise be mixed together. Each layer contains only the excipients compatible with its specific drug, eliminating retarding interactions.
3Reliability
If rosuvastatin is formulated with excipients that protect against oxidative degradation, then stability is improved, but the formulation complexity and manufacturing steps increase
Solution Approach 1:
The bi-layer structure allows inclusion of antioxidants and moisture barriers specifically in the rosuvastatin layer without affecting the ezetimibe layer formulation. This targeted approach provides comprehensive protection against oxidative degradation and moisture sensitivity while keeping the overall formulation manageable through clear layer separation.
Solution Approach 2:
Antioxidants and moisture-sensitive excipients are locally applied only where needed (in the rosuvastatin layer) rather than throughout the entire formulation. This localized protection strategy improves stability while minimizing the overall complexity by avoiding unnecessary additives in the ezetimibe layer.
4Reliability
If ezetimibe is used to reduce intestinal cholesterol absorption, then LDL reduction efficacy is improved, but the drug's water insolubility creates formulation and dissolution challenges
Solution Approach 1:
The ezetimibe layer is formulated with locally optimized excipients including surfactants and solubility-enhancing agents that specifically address ezetimibe's water insolubility. This localized formulation approach improves dissolution and absorption without requiring modification of the entire tablet formulation or compromising the drug's efficacy.
Data Source
AI summary
Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.